These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 24565016)
1. New applications of disease genetics and pharmacogenetics to drug development. Roses AD; Saunders AM; Lutz MW; Zhang N; Hariri AR; Asin KE; Crenshaw DG; Budur K; Burns DK; Brannan SK Curr Opin Pharmacol; 2014 Feb; 14():81-9. PubMed ID: 24565016 [TBL] [Abstract][Full Text] [Related]
2. The Effect of the APOE Genotype on Individual BrainAGE in Normal Aging, Mild Cognitive Impairment, and Alzheimer's Disease. Löwe LC; Gaser C; Franke K; PLoS One; 2016; 11(7):e0157514. PubMed ID: 27410431 [TBL] [Abstract][Full Text] [Related]
3. Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease). Roses AD; Saunders AM; Huang Y; Strum J; Weisgraber KH; Mahley RW Pharmacogenomics J; 2007 Feb; 7(1):10-28. PubMed ID: 16770341 [TBL] [Abstract][Full Text] [Related]
4. The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety. Roses AD Neuropsychopharmacology; 2009 Jan; 34(1):6-17. PubMed ID: 18923406 [TBL] [Abstract][Full Text] [Related]
5. TOMM40 and APOE Gene Expression and Cognitive Decline in Japanese Alzheimer's Disease Subjects. Mise A; Yoshino Y; Yamazaki K; Ozaki Y; Sao T; Yoshida T; Mori T; Mori Y; Ochi S; Iga JI; Ueno SI J Alzheimers Dis; 2017; 60(3):1107-1117. PubMed ID: 28984592 [TBL] [Abstract][Full Text] [Related]
6. Monitoring disease progression in mild cognitive impairment: Associations between atrophy patterns, cognition, APOE and amyloid. Falahati F; Ferreira D; Muehlboeck JS; Eriksdotter M; Simmons A; Wahlund LO; Westman E Neuroimage Clin; 2017; 16():418-428. PubMed ID: 28879083 [TBL] [Abstract][Full Text] [Related]
7. The TOMMORROW study: Design of an Alzheimer's disease delay-of-onset clinical trial. Burns DK; Chiang C; Welsh-Bohmer KA; Brannan SK; Culp M; O'Neil J; Runyan G; Harrigan P; Plassman BL; Lutz M; Lai E; Haneline S; Yarnall D; Yarbrough D; Metz C; Ponduru S; Sundseth S; Saunders AM Alzheimers Dement (N Y); 2019; 5():661-670. PubMed ID: 31720367 [TBL] [Abstract][Full Text] [Related]
8. Butyrylcholinesterase K and Apolipoprotein E-ɛ4 Reduce the Age of Onset of Alzheimer's Disease, Accelerate Cognitive Decline, and Modulate Donepezil Response in Mild Cognitively Impaired Subjects. De Beaumont L; Pelleieux S; Lamarre-Théroux L; Dea D; Poirier J; J Alzheimers Dis; 2016 Oct; 54(3):913-922. PubMed ID: 27567841 [TBL] [Abstract][Full Text] [Related]
9. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease. Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875 [TBL] [Abstract][Full Text] [Related]
10. Apolipoprotein E genotype is not associated with cognitive impairment in older adults with bipolar disorder. Kerr DS; Stella F; Radanovic M; Aprahamian I; Bertollucci PH; Forlenza OV Bipolar Disord; 2016 Feb; 18(1):71-7. PubMed ID: 26877211 [TBL] [Abstract][Full Text] [Related]
11. Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Vellas B; Carrillo MC; Sampaio C; Brashear HR; Siemers E; Hampel H; Schneider LS; Weiner M; Doody R; Khachaturian Z; Cedarbaum J; Grundman M; Broich K; Giacobini E; Dubois B; Sperling R; Wilcock GK; Fox N; Scheltens P; Touchon J; Hendrix S; Andrieu S; Aisen P; Alzheimers Dement; 2013 Jul; 9(4):438-44. PubMed ID: 23809364 [TBL] [Abstract][Full Text] [Related]
12. Brain atrophy rates in first degree relatives at risk for Alzheimer's. Lampert EJ; Roy Choudhury K; Hostage CA; Rathakrishnan B; Weiner M; Petrella JR; Doraiswamy PM; Neuroimage Clin; 2014; 6():340-6. PubMed ID: 25379448 [TBL] [Abstract][Full Text] [Related]
13. Genetic variation in APOE cluster region and Alzheimer's disease risk. Cervantes S; Samaranch L; Vidal-Taboada JM; Lamet I; Bullido MJ; Frank-García A; Coria F; Lleó A; Clarimón J; Lorenzo E; Alonso E; Sánchez-Juan P; Rodríguez-Rodríguez E; Combarros O; Rosich M; Vilella E; Pastor P Neurobiol Aging; 2011 Nov; 32(11):2107.e7-17. PubMed ID: 21752496 [TBL] [Abstract][Full Text] [Related]
15. Post Hoc Analyses of ApoE Genotype-Defined Subgroups in Clinical Trials. Kennedy RE; Cutter GR; Wang G; Schneider LS J Alzheimers Dis; 2016; 50(4):1205-15. PubMed ID: 26836180 [TBL] [Abstract][Full Text] [Related]
16. Topographical APOE ɛ4 Genotype Influence on Cerebral Metabolism in the Continuum of Alzheimer's Disease: Amyloid Burden Adjusted Analysis. Seo EH; Kim SH; Park SH; Kang SH; Choo IH; J Alzheimers Dis; 2016 Sep; 54(2):559-68. PubMed ID: 27567846 [TBL] [Abstract][Full Text] [Related]
17. Delayed rather than decreased BOLD response as a marker for early Alzheimer's disease. Rombouts SA; Goekoop R; Stam CJ; Barkhof F; Scheltens P Neuroimage; 2005 Jul; 26(4):1078-85. PubMed ID: 15961047 [TBL] [Abstract][Full Text] [Related]
18. Accelerated progression from mild cognitive impairment to dementia among APOE ε4ε4 carriers. Xu WL; Caracciolo B; Wang HX; Santoni G; Winblad B; Fratiglioni L J Alzheimers Dis; 2013; 33(2):507-15. PubMed ID: 23247007 [TBL] [Abstract][Full Text] [Related]
20. Independent and Interactive Influences of the APOE Genotype and Beta-Amyloid Burden on Cognitive Function in Mild Cognitive Impairment. Seo EH; Kim SH; Park SH; Kang SH; Choo IH; J Korean Med Sci; 2016 Feb; 31(2):286-95. PubMed ID: 26839485 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]